Rheumatology International最新文献

{"title":"Successful infliximab therapy in systemic sarcoidosis presenting with giant leg ulcers: a case based review.","authors":"Nabil Belfeki, Nadia Ghariani Fetoui, Nour El Imene Ouni, Juliette Avci, Renaud Guedec-Ghelfi, Sonia Kammoun, Nouha Ghriss","doi":"10.1007/s00296-025-05887-3","DOIUrl":"10.1007/s00296-025-05887-3","url":null,"abstract":"<p><p>Sarcoidosis is a chronic granulomatous inflammatory disease that primarily affects the lungs and skin. Cutaneous involvement occurs in approximately 30% of cases. We report herewith a rare case of a 55-year-old man with chronic, non-healing bilateral leg ulcers, ultimately diagnosed as ulcerative cutaneous sarcoidosis through histopathological confirmation. Giant leg ulcers complicating systemic sarcoidosis is rare and its management is challenging because there are no specific recommendation. In our case, a 24-month course of intravenous infliximab associated with oral prednisone induced sustained clinical remission. The current decline is three years. The aim of our work is to review the clinical presentation and management of ulcerative cutaneous sarcoidosis and compare them to reported cases in literature.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"136"},"PeriodicalIF":3.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The broad range of self-management strategies that people with rheumatic and musculoskeletal conditions apply: an online survey using a citizen science approach.","authors":"E Te Braake, R Schriemer, C Grünloh, S Ahoud, T Asselberghs, V Bodelier, D Hansen, C Ophuis, R Wolkorte","doi":"10.1007/s00296-025-05842-2","DOIUrl":"10.1007/s00296-025-05842-2","url":null,"abstract":"<p><p>Rheumatic and musculoskeletal diseases (RMDs) cause several restrictions in daily living. Self-management is an important aspect of managing RMDs. However, little is known about the self-management strategies that are currently applied in daily life. This study aimed to identify the current self-management strategies that people with RMDs apply through a citizen science approach. An online survey was iteratively developed together with people with RMDs. The survey was distributed among people with all types of RMDs. Survey responses were collected within Qualtrics, and once anonymized, analysed using Atlas.ti. General self-management strategies and motivations to start performing a strategy were deductively coded by two reviewers, after consultations with patient partners. 250 complete surveys were collected. 91.2% of the respondents were female. 1305 self-management strategies were mentioned, and 669 elaborations were given. Most participants applied self-management strategies within the 'physical activity' category in their daily lives (e.g., walking, biking). Motivations to start performing a certain self-management strategy mostly originated from the bodily functioning dimension (e.g., reducing pain). 1275 facilitators to start a self-management strategy were mentioned, which were mostly related to the 'support' category. Barriers (N = 480) were most frequent in the 'condition-related' category. Self-management is an important aspect of managing a person's condition in daily life. People choose one or several strategies based on the challenge they are facing, depending on their feasibility and preferences in line with their personal context. The comprehensive overview of strategies informs both patients and healthcare professionals to support a personalized self-management journey.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"135"},"PeriodicalIF":3.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Referral patterns, influencing factors, and satisfaction related to referrals of patients with rheumatic diseases to other healthcare professionals: an online survey of rheumatologists.","authors":"Khalid A Alnaqbi, Mohammed Alaswad, Amr A A Mahmoud, Suad Hannawi","doi":"10.1007/s00296-025-05889-1","DOIUrl":"10.1007/s00296-025-05889-1","url":null,"abstract":"<p><p>Managing rheumatic diseases requires teamwork, but referral patterns and challenges remain poorly understood. This study explored rheumatologists' perspectives on referral patterns in the Gulf countries. We conducted a web-based, 21-question cross-sectional survey between November and December 2024, collecting data on rheumatologists' demographics, referral patterns, influencing factors, and satisfaction. Participants were recruited through email invitations, WhatsApp groups and snowball sampling. Statistical analyses included descriptive and inferential methods, such as subgroup comparisons and logistic regression, to identify predictors of referral frequency and satisfaction. A total of 149 rheumatologists participated, with 58.4% being consultants. Approximately 55% had up to 10 years of post-training experience. The primary referral method was electronic health records (EHR) (84.8%). In the three months preceding the survey, 36.3% made 0-10 referrals, while 35.6% made over 20. Dermatology (85.5%) and physiotherapy (79.5%) were the most referred specialties, aligning with psoriatic arthritis and systemic lupus erythematosus as the most referred diseases. Most rheumatologists (78%) often or always followed up on referrals, and 37.4% reported moderate changes in their referral decision-making over time. Key influences on referral decisions included patient-, practice-, and diagnostic-related factors. Patient gender preference had no impact. Multidisciplinary meetings (78.2%), access to updated clinical guidelines (76.5%), attending multidisciplinary continuing medical education or training programs (67.2%), and improved EHR referral systems (64.7%) were the top resources for improving referrals. Satisfaction post-referral was affected by various factors such as patients' experiences post-referral (61.5%), and healthcare professionals' responsiveness to their questions (54.2%). Logistic regression analysis showed that age, employment status, practice setting, and geographical location were associated with referral decisions. This study is the first to provide valuable insights into referral practices among Gulf rheumatologists, identifying key influencing factors and areas for improvement. Findings suggest that enhancing EHR systems, multidisciplinary meetings, and clinical guidelines can optimize referrals and interdisciplinary care.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"134"},"PeriodicalIF":3.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease activity score is associated with vertebral fragility fractures in patients with rheumatoid arthritis: a cross-sectional multidisciplinary study.","authors":"Chiara Lopez, Simone Parisi, Mirko Parasiliti-Caprino, Guglielmo Beccuti, Francesco Ghellere, Maria Chiara Ditto, Ezio Ghigo, Fabio Broglio, Enrico Fusaro","doi":"10.1007/s00296-025-05877-5","DOIUrl":"10.1007/s00296-025-05877-5","url":null,"abstract":"<p><p>Rheumatoid Arthritis (RA) is associated with osteometabolic alterations. This study aims to estimate the prevalence of osteometabolic complications and to explore the potential association with disease parameters in patients with RA. This cross-sectional study enrolled consecutive patients with diagnosis of RA, admitted to Rheumatology Unit of our Hospital and referred to the Endocrinology Unit for the assessment of osteometabolic health. Anamnestic, anthropometric, biochemical and instrumental data were collected for each subject. The prevalence of osteometabolic alterations was 35% for sarcopenia, 41% for osteoporosis and 28% for vertebral fragility fractures in a population of 110 RA patients. At multivariable analysis, copeptin showed direct association (β-coeff 0.006; p = 0.015) with lower lumbar bone mineral density (BMD) values on dual-energy X-ray absorptiometry (DXA). Disease Activity Score for 28 joints with C-Reactive Protein (DAS28-CRP) (OR 1.632; p = 0.031) proved to be associated with vertebral fragility fractures, correcting for age, sex, body mass index (BMI) and disease parameters. Furthermore, DAS28-CRP (β-coeff 0.584; p = 0.001), steroid therapy (β-coeff 0.993; p = 0.013), and old age (β-coeff 0.040; p = 0.013) were directly associated with sarcopenia score (SARC-F), while male sex showed indirect association (β-coeff - 1.027; p = 0.036), correcting for autoantibody positivity and BMI. In the last model, copeptin resulted indirectly associated with fat mass index on DXA (β-coeff - 0.236, p = 0.049), using age and disease parameters, as covariates. RA is characterized by a high prevalence of osteometabolic complications, caused by a complex interplay between autoimmune and metabolic pathways. Management of osteometabolic health in RA patients should be a shared decision making between rheumatologist and endocrinologist.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"133"},"PeriodicalIF":3.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic foot in the context of rheumatic diseases: pathogenesis and treatment approaches.","authors":"Dana Bekaryssova, Marlen Yessirkepov, Ak-Uke Rakisheva, Assylkhan Bakytzhan","doi":"10.1007/s00296-025-05890-8","DOIUrl":"10.1007/s00296-025-05890-8","url":null,"abstract":"<p><p>Diabetic foot is a frequent and debilitating complication of diabetes mellitus that significantly impairs quality of life and increases the risk of disability and amputation. This review examines the multifactorial pathogenesis of diabetic foot, focusing on its increased incidence and severity in patients with rheumatic diseases. The development of diabetic foot is driven by diabetic neuropathy, peripheral vascular disease, and infection. In patients with rheumatic diseases, chronic systemic inflammation and vascular dysfunction further accelerate tissue damage and impair wound healing. Long-term use of pharmacologic agents such as glucocorticoids and nonsteroidal anti-inflammatory drugs also contributes to metabolic imbalance, immune suppression, and vascular complications, increasing the risk of ulceration and infection. Rheumatic disease-related joint deformities and altered foot biomechanics add mechanical stress, exacerbating the condition. Effective management of diabetic foot in patients with rheumatic diseases requires a multidisciplinary approach. This includes early diagnosis, strict glycemic control, modulation of systemic inflammation, optimization of vascular health, and preventive foot care strategies. Addressing both metabolic and rheumatologic components is essential to reduce the risk of severe outcomes such as chronic infection and limb amputation. Understanding the interplay between diabetes and rheumatic diseases is crucial for improving clinical outcomes. Targeted, integrated interventions are key to preventing complications and enhancing the quality of life for affected patients.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"132"},"PeriodicalIF":3.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review.","authors":"Jean-Baptiste Vulsteke, Petra De Haes, Minoru Satoh, Ben Van Cleynenbreugel, Benoit Beuselinck, Xavier Bossuyt, Ellen De Langhe","doi":"10.1007/s00296-025-05886-4","DOIUrl":"10.1007/s00296-025-05886-4","url":null,"abstract":"<p><p>To describe the clinical features and cancer risk in patients with dermatomyositis (DM) and anti-TIF1β autoantibodies without other DM-specific autoantibodies (anti-TIF1β-monospecific DM) through a case-based review. Case report of anti-TIF1β-monospecific cancer-associated DM and literature review of cases of anti-TIF1β-monospecific DM. We describe a case of a person with cancer-associated DM in whom we identified anti-TIF1β autoantibodies through immunoprecipitation-mass spectrometry. He had typical cutaneous involvement, mild myositis and a good response to medical therapy after curative treatment of an underlying renal cell cancer. A literature search of Pubmed and Scopus identified 9 more persons with anti-TIF1β-monospecific DM revealing a homogeneous phenotype with typical cutaneous involvement, mild to absent muscular involvement and absence of interstitial lung disease. Two out of ten (20%) had cancer-associated DM. Anti-TIF1β-monospecific DM represents a homogeneous subset of DM characterized by typical cutaneous involvement, mild to absent myositis and potentially an elevated cancer risk (20%). More cohort studies with adequate detection methods are needed to formally assess the cancer risk as compared to anti-TIF1γ and other DM-specific autoantibodies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"131"},"PeriodicalIF":3.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current concepts on pathogenesis, diagnosis and management of hepatic sarcoidosis.","authors":"Nabil Belfeki, Sonia Kammoun, Nouha Ghriss, Charif Eldirani, Arsene Mekinian","doi":"10.1007/s00296-025-05888-2","DOIUrl":"10.1007/s00296-025-05888-2","url":null,"abstract":"<p><p>Sarcoidosis is an inflammatory multisystemic granulomatosis of unknown cause, with a wide range of clinical features, characterized by the presence of non-caseating granulomas. Liver is the third involved organ after lungs and lymph nodes, with a reported prevalence of hepatic involvement in 5 to 25% of systemic symptomatic sarcoidosis. The immunopathogenesis of sarcoidosis is still unknown but it seems to involve the innate and adaptive immune actors in response to a putative antigen in genetically predisposed individuals. Because of its paucisymptomatic presentation, hepatic sarcoidosis may be underdiagnosed. Unspecified impaired general condition, fever, abdominal pain, and jaundice are the main symptoms associated with liver sarcoidosis. Frequently, laboratory liver tests are abnormal. Imaging tools may reveal liver nodular enlargement but can be totally normal. Liver biopsy is often required to confirm the diagnosis. A meticulous workup is mandatory to rule out differential diagnosis of hepatic granuloma. Portal hypertension and liver cirrhosis are the most prevalent complications of hepatic sarcoidosis. Treatment is not necessary in all cases and first line treatment in symptomatic patients requires corticosteroids and/or ursodeoxycholic acid. Immunosuppressants and biologics could be used as second line agents. In severe cases, liver transplantation is indicated.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"130"},"PeriodicalIF":3.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings.","authors":"Cay-Benedict von der Decken, Stefan Kleinert, Matthias Englbrecht, Kirsten Karberg, Georg Gauler, Monika Ronneberger, Praxedis Rapp, Florian Schuch, Joerg Wendler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Peter Bartz-Bazzanella","doi":"10.1007/s00296-025-05861-z","DOIUrl":"10.1007/s00296-025-05861-z","url":null,"abstract":"<p><p>More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"129"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depressive symptoms are highly prevalent and associated with fatigue and pain catastrophizing in the Hypermobility Spectrum Disorders and hypermobile Ehlers Danlos syndrome: a cross-sectional study.","authors":"Elizabeth Kathleen Stockton Fletcher, Ashley Loren Fischer, Ranita Harpreet Kaur Manocha","doi":"10.1007/s00296-025-05869-5","DOIUrl":"10.1007/s00296-025-05869-5","url":null,"abstract":"<p><p>Individuals living with Hypermobility Spectrum Disorders and the hypermobile Ehlers-Danlos syndrome (HSD/hEDS) often experience recurrent joint injury, chronic pain, and fatigue. Although generalized anxiety has been recognized as a common comorbidity with HSD/hEDS, minimal research has examined depressive symptoms in this population. The purpose of this investigation was to describe the prevalence, nature, and severity of depressive symptoms in the HSD/hEDS population, and to explore associations with other potential confounding factors. All individuals with HSD/hEDS referred to a specialized connective tissue disorder Physical Medicine & Rehabilitation clinic were asked to self-report demographic data and complete the 9-item Patient Health Questionnaire (PHQ-9), 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), Pain Catastrophizing Symptoms (PCS) questionnaire, and Fatigue Severity Scale (FSS) at their initial clinic visit. Data was prospectively collected between January 2019 and December 2024. Descriptive statistics were performed. A Spearman correlation matrix was used to identify relevant factors associated with depressive symptoms. Relationships emerging as significant (p < 0.001) were further analyzed using independent sample Mann-Whitney U-tests. Fifty-nine individuals (53 female, mean ± SD age: 34.4 ± 11 years) were included, with a mean ± SD PHQ-9 score of 11.2 ± 5.9, indicating moderate depressive symptom severity. 53% of participants (n = 31) met criteria for major depressive disorder (PHQ-9 ≥ 10). Higher pain catastrophizing (ρ = 0.611, p < 0.001) and higher fatigue scores (ρ = 0.593, p < 0.001) were both associated with significantly higher depressive symptoms, but there were no associations with respect to age, working status, and number of alcoholic drinks consumed per week. This research suggests that depression is highly prevalent in patients experiencing HSD/hEDS. There is also a strong association between pain catastrophizing and fatigue in those experiencing depressive symptoms. The interaction between depressive symptoms, pain catastrophizing, and fatigue should be considered in the holistic management of HSD/hEDS.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"128"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study.","authors":"Chrysanthi Staveri, Chrysa Lykoura, Konstantinos Melissaropoulos, Stamatis-Nick C Liossis","doi":"10.1007/s00296-025-05879-3","DOIUrl":"10.1007/s00296-025-05879-3","url":null,"abstract":"<p><p>Treatment of Systemic Lupus Erythematosus (SLE) remains challenging. The aim of this real-world evidence study of patients with refractory SLE treated with rituximab (RTX) was to explore for any potential long-term effect(s) of this particular B cell depletion approach. This study included patients with SLE who had i) received at least 1 cycle of RTX and had ii) an at least 10 yr of follow-up after their first RTX infusion. Outcomes were assessed at 1 year and at their latest evaluation that was ≥ 10 yr after RTX treatment initiation. In cases where the SLE Disease Activity Index 2000 (cSLEDAI-2 k) was employed, a response was defined as a cSLEDAI-2 k of less than 4 in cases where the cSLEDAI-2 k was ≥ 4. In cases where the cSLEDAI-2 k was 2-4 at baseline, a response was defined as a cSLEDAI-2 k of 0. RTX was administered in 62 patients with SLE. For this real-world evidence study 23 patients (25 cases) with SLE (all Caucasian female, age range: 14-72 yr, mean: 31 yr) with active or relapsing disease, fulfilling inclusion criteria were enrolled. RTX treatment was associated with a response rate of 68.75% after 1 yr and 75% after ≥ 10 yr. The median cSLEDAI-2 K score decreased from 5.83 ± 3.70 at baseline to 1.95 ± 2.40 (p < 0.001) at 1 yr and to 2.37 ± 3.00 (p < 0.001) at the ≥ 10 yr time-point of follow-up. Our data suggest that RTX may indeed represent an alternative therapeutic option in patients with SLE refractory to standard treatment with an acceptable safety profile.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"127"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}